Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial.
CirculationAug 18, 2026 (epub)
Marc P Bonaca, Mario Enrico Canonico, Na Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of bempedoic acid on major adverse limb events (MALE) in 1,624 patients with peripheral artery disease (PAD). Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64; P = 0.018) and total MALE by 45% (relative risk, 0.55; P = 0.007), indicating significant benefits for this high-risk population.
Key findings
- Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64; P = 0.018).
- Total MALE was reduced by 45% (relative risk, 0.55; P = 0.007).
- First MACE-4 or MALE was reduced by 13% overall (hazard ratio, 0.87).
- Total MACE-4 or MALE was reduced with a relative risk of 0.81 overall.
Why it matters
The study highlights the importance of managing low-density lipoprotein cholesterol in patients with PAD, as it can significantly reduce the risk of major adverse events. This is crucial for improving patient outcomes in a population already at high risk for cardiovascular complications.